An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Clinical trial NCT06617793 · RECRUITING
Trial details
- NCT number
- NCT06617793
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-24
- Primary completion
- 2030-08-07
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.